Zilka Norbert, Filipcik Peter, Koson Peter, Fialova Lubica, Skrabana Rostislav, Zilkova Monika, Rolkova Gabriela, Kontsekova Eva, Novak Michal
Axon Neuroscience GmbH, Rennweg 95b, 1030 Vienna, Austria.
FEBS Lett. 2006 Jun 26;580(15):3582-8. doi: 10.1016/j.febslet.2006.05.029. Epub 2006 May 22.
Truncated tau protein is the characteristic feature of human sporadic Alzheimer's disease. We have identified truncated tau proteins conformationally different from normal healthy tau. Subpopulations of these structurally different tau species promoted abnormal microtubule assembly in vitro suggesting toxic gain of function. To validate pathological activity in vivo we expressed active form of human truncated tau protein as transgene, in the rat brain. Its neuronal expression led to the development of the neurofibrillary degeneration of Alzheimer's type. Furthermore, biochemical analysis of neurofibrillary changes revealed that massive sarcosyl insoluble tau complexes consisted of human Alzheimer's tau and endogenous rat tau in ratio 1:1 including characteristic Alzheimer's disease (AD)-specific proteins (A68). This work represents first insight into the possible causative role of truncated tau in AD neurofibrillary degeneration in vivo.
截短的tau蛋白是人类散发性阿尔茨海默病的特征性表现。我们已经鉴定出构象不同于正常健康tau蛋白的截短tau蛋白。这些结构不同的tau蛋白亚群在体外促进了异常的微管组装,提示功能获得性毒性。为了在体内验证其病理活性,我们将人截短tau蛋白的活性形式作为转基因在大鼠脑中表达。其神经元表达导致了阿尔茨海默病类型的神经纤维变性。此外,对神经纤维变化的生化分析显示,大量十二烷基肌氨酸不溶性tau蛋白复合物由人阿尔茨海默病tau蛋白和内源性大鼠tau蛋白以1:1的比例组成,其中包括阿尔茨海默病(AD)特异性特征蛋白(A68)。这项工作首次揭示了截短tau蛋白在体内AD神经纤维变性中可能的致病作用。